BackAclaris Therapeutics Overview
Aclaris Therapeutics Inc

Aclaris Therapeutics Target Price

See Aclaris Therapeutics's analyst price targets ($11) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$6.31

Average Target Price

$11.0074.5% upside

3 analysts in the last 4 months

High: $12 | Low: $10

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-05-05Piper SandlerBiren Amin$1174.5% upsideOpen
2026-05-05Guggenheim$1290.3% upsideOpen
2026-04-29WedbushMartin Fan$1058.6% upsideOpen
2026-04-16UBS$1058.6% upsideOpen
2026-01-30Craig-HallumAdam Vogel$1058.6% upsideOpen
2024-11-19BTIGJulian Harrison$826.9% upsideOpen
2024-11-19JefferiesRoger Song$711% upsideOpen
2024-11-06Stifel NicolausAlex Thompson$352.4% downsideOpen
2022-12-01Goldman Sachs$25296.5% upsideOpen

Aclaris Therapeutics (ACRS) FAQ

The latest target price for ACRS is $11. Investors often review this figure alongside Aclaris Therapeutics's historical trend and sector peers before judging valuation or financial health.

Aclaris Therapeutics trades near $6.31 while the consensus target sits at $11 (74.5% upside). Targets are estimates based on earnings forecasts and valuation models; they change when analysts update ratings or revise models. Compare the average with the high and low targets for a fuller picture.

After noting ACRS's target price ($11), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Aclaris Therapeutics's target price against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.